Artisan Partners Limited Partnership Has $4.59 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Artisan Partners Limited Partnership cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 92.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 62,591 shares of the biopharmaceutical company’s stock after selling 752,150 shares during the period. Artisan Partners Limited Partnership’s holdings in Halozyme Therapeutics were worth $4,590,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of HALO. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $25,000. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at about $32,000. Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $34,000. Finally, Clearstead Advisors LLC grew its position in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. This trade represents a 2.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 49,398 shares of company stock worth $3,650,592 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.4%

NASDAQ HALO opened at $69.53 on Friday. The firm has a market capitalization of $8.21 billion, a PE ratio of 27.92, a price-to-earnings-growth ratio of 0.28 and a beta of 0.97. The business’s 50-day moving average price is $72.62 and its two-hundred day moving average price is $70.68. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same period in the prior year, the firm earned $1.26 earnings per share. Halozyme Therapeutics’s revenue was up 51.6% compared to the same quarter last year. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on HALO shares. Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Citizens Jmp upped their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Finally, Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.